CRISPR Therapeutics AG (CRSP) Price to Book (2016 - 2026)

CRISPR Therapeutics AG has disclosed Price to Book across 11 years of filings, most recently posting 3.02 for Q2 2026.

• In Q2 2026, Price to Book rose 20.15% year-over-year to 3.02; the TTM figure through Jun 2026 stood at 3.02 (up 20.15% YoY), while the FY2025 annual figure was 2.62, up 49.8% from the prior year.
• Price to Book came in at 3.02 for Q2 2026 at CRISPR Therapeutics AG, up from 2.53 in the prior quarter.
• In the past five years, Price to Book ranged from a high of 3.18 in Q3 2025 to a low of 1.61 in Q1 2025.
• Average Price to Book over 5 years is 2.35, with a median of 2.39 recorded in 2023.
• Year-over-year, Price to Book plunged 57.66% in 2022 and surged 57.27% in 2026.
• Over 5 years, Price to Book stood at 1.7 in 2022, then surged by 56.39% to 2.66 in 2023, then sank by 34.37% to 1.75 in 2024, then jumped by 49.8% to 2.62 in 2025, then increased by 15.36% to 3.02 in 2026.
• Per Business Quant data, the three most recent Price to Book figures were 3.02 in Q2 2026, 2.53 in Q1 2026, and 2.62 in Q4 2025.